Sagent Pharmaceuticals (SGNT) - NASDAQ
  • Mon, Jul. 11, 12:48 PM
    | Mon, Jul. 11, 12:48 PM
  • Mon, Jul. 11, 11:00 AM
    | Mon, Jul. 11, 11:00 AM
  • Mon, Jul. 11, 9:15 AM
    | Mon, Jul. 11, 9:15 AM
  • Mon, Jul. 11, 8:25 AM
    • Tokyo-based Nichi-Iko Pharmaceutical has inked an agreement to acquire Sagent Pharmaceuticals (NASDAQ:SGNT) for ~$736M or $21.75 per share. The all-cash tender offer will commence within 15 business days.
    • The deal will enhance Nichi-Iko's presence in the U.S. market, specifically in injectables and, eventually, biosimilars.
    • Sagent is up 39% premarket on robust volume.
    | Mon, Jul. 11, 8:25 AM
  • Wed, Jan. 13, 12:43 PM
    | Wed, Jan. 13, 12:43 PM | 24 Comments
  • Mar. 26, 2015, 5:39 PM
     
    • Top gainers, as of 5:15 p.m.: CMCM +12.8%. OXM +9.2%. SFY +4.9%. SGMS +4.3%. RICE +3.9%.
    • Top losers, as of 5:15 p.m.: WTI -6.6%. GME -5.7%. RH -5.1%. SGNT -3.9%. SSE -3.6%.
    | Mar. 26, 2015, 5:39 PM
  • Mar. 26, 2015, 12:49 PM
    | Mar. 26, 2015, 12:49 PM | 2 Comments
  • Dec. 17, 2014, 12:46 PM
    | Dec. 17, 2014, 12:46 PM
  • Sep. 9, 2013, 2:14 PM
    • Sagent Pharmaceuticals (SGNT -9.2%) slides after announcing a 4.4M share offering.
    • The company will be offering 3,384,097 shares and other selling shareholders will sell 1,057,530 shares.
    • The underwriters will have a 30-day option to purchase up to an additional 666,244 shares as needed.
    • The company intends to use the net proceeds for general corporate purposes.
    | Sep. 9, 2013, 2:14 PM
  • Sep. 9, 2013, 12:46 PM
    | Sep. 9, 2013, 12:46 PM
  • Jun. 7, 2013, 3:24 PM

    Sagent Pharmaceuticals (SGNT +0.7%) says it's initiated a voluntary nationwide recall of three lots of Vecuronium Bromide for Injection due to the discovery of an elevated impurity detected during routine quality testing of stability samples. The elevated impurity has the potential to result in prolonged neuromuscular blockade for critically ill patients with renal failure. The company said it is not aware of any adverse patient events resulting from the use of this product and will continue its investigation.

    | Jun. 7, 2013, 3:24 PM
  • May 6, 2013, 2:47 PM

    Sagent Pharmaceuticals (SGNT -0.2%) gives back an early 9% lead to trade back into the red today following an earlier Q1 earnings beat and the announcement that it's acuired the remaining 50% interest in its China joint venture Kanghong Sagent Pharmaceutical for $25M. The company also says it expects FY13 net revenue to be around $220M to $250M, and net income to be between $5M and $15M. Street estimates are for the company to report revenue of $238M and net income of $2.4M.

    | May 6, 2013, 2:47 PM
  • Aug. 10, 2012, 2:41 PM

    Wall Street firms are responding today to Sagent Pharmaceuticals' (SGNT -2.6%) revised outlook yesterday, which took the shares down over 25% during the trading session. RBC cut the shares to Sector Perform on the news, citing a lack of earnings visibility over the near term, while Needham, cut its price target to $20 from $25, saying the company "remains its own worst enemy" when it comes to managing estimates and maintaining management's credibility.

    | Aug. 10, 2012, 2:41 PM
  • Aug. 31, 2011, 4:26 PM

    Sagent Pharmaceuticals (SGNT) receives FDA approval for its Orphenadrine Citrate Injection, USP, a skeletal muscle relaxant. Shares +0.1% AH.

    | Aug. 31, 2011, 4:26 PM
  • Aug. 19, 2011, 4:32 PM

    Sagent Pharmaceuticals (SGNT +4%) closed higher today after announcing the launch of its neuromuscular blocking agent vecuronium bromide - which is currently in short supply in the U.S. - for injection in 10 and 20 mg single-use vials.

    | Aug. 19, 2011, 4:32 PM
  • Jun. 23, 2011, 10:57 AM

    Needham downgrades Sagent Pharmaceuticals (SGNT -6.15%) on valuation, saying it's already reached the 12-month price target set when it initiated coverage three weeks ago. The stock is up 62% since its April IPO.

    | Jun. 23, 2011, 10:57 AM
Company Description
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products. With a primary focus on generic injectable pharmaceuticals, the company offers its customers a broad range of products across anti-infective,... More
Sector: Healthcare
Industry: Drugs - Generic
Country: United States